Connect Sign In
ARUP and University of Utah Health continue to research the safety and efficacy of COVID-19 convalescent plasma (CCP) in four multicenter randomized clinical trials.
Which types of innovation, adaptation, and acceleration happened in diagnostic technology companies in the face of the COVID-19 pandemic? Are the intensity and fast-moving strategies even sustainable?
A recording of an hour-long webinar updating the status of diagnostic testing for SARS-CoV-2 nearly a year after the first tests were introduced is now available to watch for free.
ARUP Laboratories has made a new resource available to laboratory leaders and others in healthcare to help explain how the first FDA-approved SARS-CoV-2 vaccines work.
ARUP announced the availability to clients nationwide of a combined test to detect and differentiate COVID-19, influenza, and respiratory syncytial virus (RSV).
ARUP Laboratories now offers testing to detect the virus that causes COVID-19 using saliva specimens. The molecular diagnostic test is available with preapproval to ARUP clients nationwide.
As a national EAP program to deliver COVID-19 convalescent plasma to hospitalized patients with COVID-19 concludes, researchers are transitioning to multicenter randomized clinical trials.
When supplies of a critical component of kits used to collect specimens for COVID-19 testing suddenly grew scarce, scientists at ARUP worked to formulate an alternative.
Self-collected saliva and deep nasal swabs collected by healthcare providers are equally effective for detecting SARS-CoV-2, the virus that causes COVID-19, according to a new study.
While many companies are laying off or furloughing employees due to the COVID-19 pandemic, ARUP is experiencing a hiring surge as the company continues to expand its COVID-19 testing capacity.
